Skip to main content


Placeholder slot

This page contains brief information about nivolumab (Opdivo) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Opdivo Injection
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Nivolumab is approved to be used alone or with other drugs to treat:

¹These uses are approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that nivolumab provides a clinical benefit in these patients.

Nivolumab is also being studied in the treatment of other types of cancer.

More About Nivolumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Nivolumab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases

Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney Cancer

NCI-MATCH Update: More Labs, New Arms, and Initial Findings

Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the Brain

Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer

Can Age Affect Response to Immune Checkpoint Inhibitors?

FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer

Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer

Nivolumab Receives Accelerated Approval from FDA for Advanced Liver Cancer

FDA Approves Nivolumab for Some Metastatic Colorectal Cancers

FDA Approves Nivolumab for Bladder Cancer

With Immunotherapy, Glimmers of Progress Against Glioblastoma

Lung Cancer Precision Medicine Trials: Adapting to Progress

Nivolumab-Based Treatments Delay Progression of Advanced Melanoma

Nivolumab Improves Overall Survival in Patients With Metastatic Melanoma Without a BRAF Mutation

New Therapies Are Changing the Outlook for Advanced Melanoma

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Nivolumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: